doi:10.1016/j.brachy.2022.01.006engLozares-Cordero, SergioGonzález Pérez, VictorPellejero-Pellejero, SantiagoRodríguez Ruiz, LuciaGuinot Rodríguez, José LuisVillafranca-Iturre, ElenaMéndez-Villamón, AgustinaGandía Martínez, AlmudenaFuentemilla-Urío, NaiaraRuggeri, RicardoFeasibility of electronic brachytherapy in cervix cancer–A dosimetric comparison of different brachytherapy techniquesART-2022-146971Introducción: This study analyzes cases in which electronic brachytherapy (eBT) led to acceptable treatment plans in cervical cancer. Findings were compared with dosimetry values obtained in 192 Ir-based treatments according to the high-risk clinical target volume (HR-CTV) and the disease stage. Material and methods: We retrospectively analyzed 48 patients with cervical cancer from two centers. The patients were treated with 192 Ir based on MRI. It was possible to use interstitial needles via an Utrecht-type applicator. Dosimetry was simulated using eBT and the parameters D90 and D98 (HR-CTV) and D2cc, D1cc, and D0.1cc (bladder, rectum, and sigmoid colon) were evaluated. The Mann-Whitney U test was used for comparison. The overall cohort of patients was analyzed, as were the sub-cohorts based on stage (FIGO stages I + IIA, IIB and III–IV). Finally, the dosimetry of the eBT plans was evaluated, and the plans obtained were classified as “good”, “acceptable”, or “poor”. Results: Statistically significant differences were found between the eBT and 192 Ir plans for D98 (HR-CTV), D1cc and D0.1cc (bladder), and D1cc and D0.1cc (sigmoid colon). A total of 31 cases (64.6%) were considered good, seven (14.6%) were considered acceptable, and 10 (20.8%) were considered poor. For volumes < 30 cc, all the plans were good or acceptable; for volumes > 30 cc, 54.3% were good, and 71.4% were good or acceptable. By stage, eBT plans for patients with stage IB–IIA disease were good in 100%, whereas those for patients with stage IIB were good in 70.6% and III–IV disease were good in 50%. Conclusions: eBT provides appropriate dosimetry for treatment of cervical cancer in selected cases.2022http://zaguan.unizar.es/record/16529310.1016/j.brachy.2022.01.006http://zaguan.unizar.es/record/165293oai:zaguan.unizar.es:165293Brachytherapy 21, 4 (2022), 389-396byhttps://creativecommons.org/licenses/by/4.0/deed.esinfo:eu-repo/semantics/openAccess